Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma.

Andreas Viardot,Georg Hess,Ralf C. Bargou,Nicholas J. Morley,Giuseppe Gritti,Maria-Elisabeth Goebeler,Karim Iskander,David Cohan,Alicia Zhang,Janet Franklin,Luke Coyle

Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma.

2020

Andreas Viardot
Georg Hess
Ralf C. Bargou
Nicholas J. Morley
Giuseppe Gritti
Maria-Elisabeth Goebeler
Karim Iskander
David Cohan
Alicia Zhang
Janet Franklin
Luke Coyle

Despite advances in standards of care, the prognosis of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains poor. In these patients, 50–74% fail to respond to next line therapy,...

Keywords:

complete response
Medicine
Immunology
Diffuse large B-cell lymphoma
relapsed refractory
Cancer research
Blinatumomab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations